Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit

Frank A. Hamilton for the NIH Gastroparesis Consortium

Research output: Contribution to journalArticle

Abstract

Background: Marijuana may be used by some patients with gastroparesis (Gp) for its potential antiemetic, orexigenic, and pain-relieving effects. Aims: The aim of this study was to describe the use of marijuana by patients for symptoms of Gp, assessing prevalence of use, patient characteristics, and patients’ perceived benefit on their symptoms of Gp. Methods: Patients with symptoms of Gp underwent history and physical examination, gastric emptying scintigraphy, and questionnaires assessing symptoms. Patients were asked about the current use of medications and alternative medications including marijuana. Results: Fifty-nine of 506 (11.7%) patients with symptoms of Gp reported current marijuana use, being similar among patients with delayed and normal gastric emptying and similar in idiopathic and diabetic patients. Patients using marijuana were younger, more often current tobacco smokers, less likely to be a college graduate, married or have income > $50,000. Patients using marijuana had higher nausea/vomiting subscore (2.7 vs 2.1; p = 0.002), higher upper abdominal pain subscore (3.5 vs 2.9; p = 0.003), more likely to be using promethazine (37 vs 25%; p = 0.05) and dronabinol (17 vs 3%; p < 0.0001). Of patients using marijuana, 51% had been using it for more than 2 years, 47% were using this once or more per day, and 81% of marijuana users rated their benefit from marijuana as better or much better. Conclusions: A subset of patients (12%) with symptoms of Gp use marijuana. Patients with severe nausea and abdominal pain were more likely to use marijuana and perceive it to be beneficial for their symptoms. Trial Registration: ClinicalTrials.gov Identifier: NCT01696747.

Original languageEnglish (US)
JournalDigestive Diseases and Sciences
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Gastroparesis
Cannabis
Gastric Emptying
Nausea
Abdominal Pain
Promethazine
Dronabinol
Antiemetics

Keywords

  • Cannabinoids
  • Cannabis
  • Dronabinol
  • Gastroparesis
  • Marijuana

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Marijuana Use in Patients with Symptoms of Gastroparesis : Prevalence, Patient Characteristics, and Perceived Benefit. / Frank A. Hamilton for the NIH Gastroparesis Consortium.

In: Digestive Diseases and Sciences, 01.01.2019.

Research output: Contribution to journalArticle

@article{1d56d4df069f4099b1eef041045c6931,
title = "Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit",
abstract = "Background: Marijuana may be used by some patients with gastroparesis (Gp) for its potential antiemetic, orexigenic, and pain-relieving effects. Aims: The aim of this study was to describe the use of marijuana by patients for symptoms of Gp, assessing prevalence of use, patient characteristics, and patients’ perceived benefit on their symptoms of Gp. Methods: Patients with symptoms of Gp underwent history and physical examination, gastric emptying scintigraphy, and questionnaires assessing symptoms. Patients were asked about the current use of medications and alternative medications including marijuana. Results: Fifty-nine of 506 (11.7{\%}) patients with symptoms of Gp reported current marijuana use, being similar among patients with delayed and normal gastric emptying and similar in idiopathic and diabetic patients. Patients using marijuana were younger, more often current tobacco smokers, less likely to be a college graduate, married or have income > $50,000. Patients using marijuana had higher nausea/vomiting subscore (2.7 vs 2.1; p = 0.002), higher upper abdominal pain subscore (3.5 vs 2.9; p = 0.003), more likely to be using promethazine (37 vs 25{\%}; p = 0.05) and dronabinol (17 vs 3{\%}; p < 0.0001). Of patients using marijuana, 51{\%} had been using it for more than 2 years, 47{\%} were using this once or more per day, and 81{\%} of marijuana users rated their benefit from marijuana as better or much better. Conclusions: A subset of patients (12{\%}) with symptoms of Gp use marijuana. Patients with severe nausea and abdominal pain were more likely to use marijuana and perceive it to be beneficial for their symptoms. Trial Registration: ClinicalTrials.gov Identifier: NCT01696747.",
keywords = "Cannabinoids, Cannabis, Dronabinol, Gastroparesis, Marijuana",
author = "{Frank A. Hamilton for the NIH Gastroparesis Consortium} and Parkman, {Henry P.} and Sharkey, {Emily P.} and Nguyen, {Linda A.} and Yates, {Katherine P.} and Abell, {Thomas L.} and Hasler, {William L.} and William Snape and John Clarke and Ron Schey and Koch, {Kenneth L.} and Braden Kuo and McCallum, {Richard W.} and Irene Sarosiek and Madhusudan Grover and Gianrico Farrugia and James Tonascia and Pasricha, {Pankaj J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10620-019-05963-2",
language = "English (US)",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",

}

TY - JOUR

T1 - Marijuana Use in Patients with Symptoms of Gastroparesis

T2 - Prevalence, Patient Characteristics, and Perceived Benefit

AU - Frank A. Hamilton for the NIH Gastroparesis Consortium

AU - Parkman, Henry P.

AU - Sharkey, Emily P.

AU - Nguyen, Linda A.

AU - Yates, Katherine P.

AU - Abell, Thomas L.

AU - Hasler, William L.

AU - Snape, William

AU - Clarke, John

AU - Schey, Ron

AU - Koch, Kenneth L.

AU - Kuo, Braden

AU - McCallum, Richard W.

AU - Sarosiek, Irene

AU - Grover, Madhusudan

AU - Farrugia, Gianrico

AU - Tonascia, James

AU - Pasricha, Pankaj J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Marijuana may be used by some patients with gastroparesis (Gp) for its potential antiemetic, orexigenic, and pain-relieving effects. Aims: The aim of this study was to describe the use of marijuana by patients for symptoms of Gp, assessing prevalence of use, patient characteristics, and patients’ perceived benefit on their symptoms of Gp. Methods: Patients with symptoms of Gp underwent history and physical examination, gastric emptying scintigraphy, and questionnaires assessing symptoms. Patients were asked about the current use of medications and alternative medications including marijuana. Results: Fifty-nine of 506 (11.7%) patients with symptoms of Gp reported current marijuana use, being similar among patients with delayed and normal gastric emptying and similar in idiopathic and diabetic patients. Patients using marijuana were younger, more often current tobacco smokers, less likely to be a college graduate, married or have income > $50,000. Patients using marijuana had higher nausea/vomiting subscore (2.7 vs 2.1; p = 0.002), higher upper abdominal pain subscore (3.5 vs 2.9; p = 0.003), more likely to be using promethazine (37 vs 25%; p = 0.05) and dronabinol (17 vs 3%; p < 0.0001). Of patients using marijuana, 51% had been using it for more than 2 years, 47% were using this once or more per day, and 81% of marijuana users rated their benefit from marijuana as better or much better. Conclusions: A subset of patients (12%) with symptoms of Gp use marijuana. Patients with severe nausea and abdominal pain were more likely to use marijuana and perceive it to be beneficial for their symptoms. Trial Registration: ClinicalTrials.gov Identifier: NCT01696747.

AB - Background: Marijuana may be used by some patients with gastroparesis (Gp) for its potential antiemetic, orexigenic, and pain-relieving effects. Aims: The aim of this study was to describe the use of marijuana by patients for symptoms of Gp, assessing prevalence of use, patient characteristics, and patients’ perceived benefit on their symptoms of Gp. Methods: Patients with symptoms of Gp underwent history and physical examination, gastric emptying scintigraphy, and questionnaires assessing symptoms. Patients were asked about the current use of medications and alternative medications including marijuana. Results: Fifty-nine of 506 (11.7%) patients with symptoms of Gp reported current marijuana use, being similar among patients with delayed and normal gastric emptying and similar in idiopathic and diabetic patients. Patients using marijuana were younger, more often current tobacco smokers, less likely to be a college graduate, married or have income > $50,000. Patients using marijuana had higher nausea/vomiting subscore (2.7 vs 2.1; p = 0.002), higher upper abdominal pain subscore (3.5 vs 2.9; p = 0.003), more likely to be using promethazine (37 vs 25%; p = 0.05) and dronabinol (17 vs 3%; p < 0.0001). Of patients using marijuana, 51% had been using it for more than 2 years, 47% were using this once or more per day, and 81% of marijuana users rated their benefit from marijuana as better or much better. Conclusions: A subset of patients (12%) with symptoms of Gp use marijuana. Patients with severe nausea and abdominal pain were more likely to use marijuana and perceive it to be beneficial for their symptoms. Trial Registration: ClinicalTrials.gov Identifier: NCT01696747.

KW - Cannabinoids

KW - Cannabis

KW - Dronabinol

KW - Gastroparesis

KW - Marijuana

UR - http://www.scopus.com/inward/record.url?scp=85075364625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075364625&partnerID=8YFLogxK

U2 - 10.1007/s10620-019-05963-2

DO - 10.1007/s10620-019-05963-2

M3 - Article

AN - SCOPUS:85075364625

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

ER -